Tarsus Pharmaceuticals Inc. (TARS) News
Filter TARS News Items
TARS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TARS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TARS News From Around the Web
Below are the latest news stories about TARSUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TARS as an investment opportunity.
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit RunTarsus Pharmaceuticals drew its inspiration from animal-health drugs. Now, the biotech stock is on a triple-digit run. |
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDexADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog. |
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to GrowHere, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025. |
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a BetThe consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats ExpectationsTarsus Pharmaceuticals ( NASDAQ:TARS ) Third Quarter 2024 Results Key Financial Results Revenue: US$48.1m (up by... |
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ...Tarsus Pharmaceuticals Inc (TARS) reports its most successful quarter with $48 million in net sales, expanded coverage, and a growing sales force. |
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue EstimatesTarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business AchievementsGenerated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across objective measures of Meibomian Gland Disease and important patient sympt |